| Document |
Document Title |
|
WO/2022/156378A1 |
Provided is a gene transcription framework, a vector system, and a genome sequence editing method and application. The gene transcription framework is based on an eukaryotic retrotransposition mechanism and may be mediated by DNA, RNA, o...
|
|
WO/2022/158571A1 |
The present invention provides a hair growth stimulant that contains at least one type of compound selected from a group of compounds respectively represented by prescribed chemical structure formulas.
|
|
WO/2022/154504A1 |
According to the present invention, it is possible to not only simply, quickly, and accurately diagnose preeclampsia or eclampsia, but also effectively prevent, ameliorate, or treat the preeclampsia or eclampsia.
|
|
WO/2022/153846A1 |
The present disclosure includes a composition for treating cancer or suppressing angiogenesis, the composition including a microRNA agonist selected from the group consisting of miR-139-3p agonists, miR-214-3p agonists, or a combination ...
|
|
WO/2022/154044A1 |
The purpose of the present invention is to provide a pharmaceutical composition for therapeutic use that is efficacious against pancreatic cancer. This problem can be solved by the pharmaceutical composition according to the present in...
|
|
WO/2022/155349A1 |
The present disclosure relates to methods of treatment and compositions for treatment of Pathological Fatigue caused by injury or disease in the body. Pathological fatigue refers to physical and mental fatigue that is caused by viral inf...
|
|
WO/2022/154127A1 |
The present invention provides a desired antibody or antibody composition by modifying a thiol group chemically introduced into an antibody. More specifically, the present invention provides an antibody composition, etc., having desired ...
|
|
WO/2022/155435A1 |
This document relates to methods and materials for treating a mammal (e.g., a human) having, or at risk of developing, a polycystic disease (e.g., a polycystic kidney disease (PKD)). For example, methods and materials that can be used to...
|
|
WO/2022/154116A1 |
The present invention provides: a compound which makes it possible to modify an antibody with a functional substance in a regioselective manner and also makes it possible to easily adjust the binding ratio between the antibody and the fu...
|
|
WO/2022/150734A1 |
The present disclosure relates to exosome systems and compositions and preservative systems and compositions as well as methods of use and methods of manufacturing of them.
|
|
WO/2022/150709A1 |
The present disclosure provides compositions and methods for inhibiting respiratory viral infections, inflammatory diseases, and/or respiratory inflammation.
|
|
WO/2022/150430A1 |
Described are methods for reducing the formation of amphetamine carbamate and amphetacarbamate in transdermal amphetamine compositions, compositions with low levels of amphetacarbamate, and methods using such compositions for transdermal...
|
|
WO/2022/149568A1 |
The present invention relates to a CRISPR-dCas (dead Cas) protein having a helix region, being capable of forming a complex with guide RNA and target RNA, and having no nuclease activity, or a CRISPR-Cas protein having nuclease activity,...
|
|
WO/2022/148870A1 |
This invention relates to the restoration of adipose tissue in patients with lipodystrophy characterised by a defective gene. A heterologous nucleic acid that encodes a therapeutic gene product is administered to the patient. The therape...
|
|
WO/2022/150381A1 |
The present invention relates to novel substituted bicyclic derivatives that can inhibit Rho-kinases and/or Rho-kinase mediated phosphorylation of myosin light chain phosphates, compositions comprising the derivatives, methods for prepar...
|
|
WO/2022/150447A1 |
The present invention advantageously provides for use of a p-EMT signature for the treatment and prognosis of head and neck cancer across demographic groups. The p-EMT signature is differentially expressed across demographic groups. The ...
|
|
WO/2022/145439A1 |
This muscular atrophy inhibitor contains a pyrimidine nucleotide or a precursor thereof as an active ingredient. This method is for inhibiting muscular atrophy through administration of a pyrimidine nucleotide or a precursor thereof.
|
|
WO/2022/145459A1 |
The present invention addresses the problem of providing a compound having Nrf2-activation action. Provided are: compounds represented by general formula (I), or compounds of the lower-polarity group among two groups of diastereomers in ...
|
|
WO/2022/145408A1 |
The present invention provides compounds that have a serotonin 5-HT2A receptor antagonist and/or inverse agonist activity, and pharmaceutically acceptable salts thereof, and also provides a serotonin 5-HT2A receptor antagonist and/or inv...
|
|
WO/2022/141977A1 |
Provided are a class of oral GSNOR inhibitors and a pharmaceutical use thereof, the structural features thereof being shown in formula I. Compared to N6022, the compound has good oral bioavailability and a longer half-life. In in vitro e...
|
|
WO/2022/145443A1 |
The purpose of the present invention is to establish a means for treating chronic kidney diseases including Alport's syndrome. The present invention provides a pharmaceutical composition characterized by containing: a) a renin/angiotensi...
|
|
WO/2022/145449A1 |
The present invention provides a hydrolase used in enzyme replacement therapy for a lysosomal storage disease. Provided is a hydrolase that is present in lysosomes and that, when deficient, causes a lysosomal storage disease, the hydro...
|
|
WO/2022/145144A1 |
The present invention provides: a pharmaceutical composition for treating X-linked sideroblastic anemia, the composition comprising a demethylating agent, in particular, 5−azacitidine or a derivative thereof; and normal erythroid cells...
|
|
WO/2022/146914A1 |
Described herein are compounds and methods of treating a disease or disorder, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, ischemic stroke, and prion disease, comprising administering a therapeutically effectiv...
|
|
WO/2022/145438A1 |
The present invention provides a PGC-1α expression promoting agent containing a pyrimidine nucleotide or precursor thereof as an active ingredient. Also provided are a muscle-building agent and a mitochondria activating agent.
|
|
WO/2022/145405A1 |
Provided is pharmaceutical composition for treating a viral respiratory tract infection, characterized by combining a compound represented by formula (I) or a pharmaceutically acceptable salt thereof and a cap-dependent endonuclease inhi...
|
|
WO/2022/145407A1 |
Provided is a medicinal composition for treating viral respiratory tract infections, said medicinal composition being characterized by comprising a combination of a compound represented by formula (I) or a pharmaceutically acceptable sal...
|
|
WO/2022/138988A1 |
The present invention provides a compound exhibiting a coronavirus 3CL protease inhibitory effect and pharmaceutically acceptable salts thereof, and a pharmaceutical composition containing the same. Further provided are crystals that are...
|
|
WO/2022/136339A1 |
The present invention pertains to the use of conjugated fumonisin (FUM) in a method to protect an animal against FUM induced mycotoxicosis, in particular to protect against a decrease in average daily weight gain, intestinal damage, live...
|
|
WO/2022/138549A1 |
Provided is a nintedanib-containing solid dispersion in which the amount of impurities originating from nintedanib contained therein is low. The present invention provides a solid dispersion containing the components (a) and (b) indica...
|
|
WO/2022/140457A1 |
The disclosure provides methods of treating a tissue, organ, organoid or organ culture, the method comprising treating a tissue, organ, organoid or organ culture in vitro with a composition comprising one or more cell turnover factors pr...
|
|
WO/2022/135072A1 |
Provided in the present invention are a coumarin compound, a preparation method therefor, and the use and a pharmaceutical composition thereof, belonging to the technical field of medicines. The coumarin compound provided in the present ...
|
|
WO/2022/138257A1 |
The present invention provides a new substance having a PDE5 inhibitory effect. This PDE5 inhibitor includes a pupae powder or an extract thereof.
|
|
WO/2022/138923A1 |
A purpose of the present invention is to provide a novel ceramide synthesis promoter. The present invention relates to a ceramide synthesis promoter including alkaline ionized water obtained by electrolyzing an aqueous solution including...
|
|
WO/2022/138944A1 |
The present disclosure provides a pharmaceutical composition for treating and/or preventing SWI/SNF complex-dysfunction cancer. More specifically, according to the present disclosure, a compound represented by formulae (1) to (23) (the f...
|
|
WO/2022/138075A1 |
The purpose of the present invention is to provide an eye drop-type eyewash composition and the like having excellent antiseptic properties. This eye drop-type eyewash composition contains 0.005-0.03 w/v% of allantoin and does not contai...
|
|
WO/2022/138792A1 |
The purpose of the present invention is to provide a suitable form for a compound, and an active pharmaceutical ingredient thereof, for the prevention and/or treatment of a disease associated with the activation of an EP2 receptor, said ...
|
|
WO/2022/138987A1 |
The present invention provides a compound exhibiting a coronavirus 3CL protease inhibitory effect and pharmaceutically acceptable salts thereof, and a pharmaceutical composition containing the same. Further provided are crystals that are...
|
|
WO/2022/138984A1 |
The present invention provides a neurite outgrowth promoter for promoting neurite growth on nerve cells of a postnatal mammalian individual for use in a condition in which an effective amount of a glial cell-derived neurotrophic factor (...
|
|
WO/2022/138793A1 |
The present application addresses the problem of providing an effective cancer treatment method. Provided is a combination between: a compound represented by general formula (I-A) (in the formula, all signs represent the same as those ...
|
|
WO/2022/137644A1 |
[Problem] To find and provide beneficial bacteria from the flora in the birth canal. [Solution] An aspect of the present disclosure is a strain DL81 bacterium belonging to the species Lactobacillus coleohominis, which has been internatio...
|
|
WO/2022/133551A1 |
The present application is directed towards compounds, pharmaceutically acceptable salts or prodrugs thereof, which are inhibitors of Histone Deacetylase (HDAC) binding or function. The compounds especially may have some selectivity for ...
|
|
WO/2022/138791A1 |
The purpose of the present invention is to provide a medicine for the prevention and/or treatment of a disease caused by activation of an EP2 receptor, said medicine containing, as an active ingredient, a compound having an antagonistic ...
|
|
WO/2022/140654A1 |
The present disclosure relates to compositions and methods related to bicyclo[2.2.1] heptanamine-containing compounds and salts thereof.
|
|
WO/2022/140248A1 |
A nutritional supplement composition formulated to minimize DNA damage and improve DNA repair includes Folate, Vitamin B12, Vitamin D and Zinc.
|
|
WO/2022/138258A1 |
The present invention provides a new substance having a PDE5 inhibitory effect. This PDE5 inhibitor includes Paecilomyces tenuipes powder or an extract thereof.
|
|
WO/2022/137964A1 |
The present invention provides a pharmaceutical composition for preventing or treating cartilage/bone/joint diseases, the pharmaceutical composition containing, as active ingredients, a substance that inhibits the signal transduction of ...
|
|
WO/2022/138938A1 |
The present invention provides a spherical culture for which quantitative analysis can be easily performed for a region including brain neurons, which is useful as a supply source of neurons for transplantation, and which can be suitably...
|
|
WO/2022/135523A1 |
Disclosed in the present invention is an application of a BMP4 protein in preparation of a drug for treating or preventing a fibroproliferative disease of an object, wherein the BMP4 protein is a free BMP4 protein or a recombinant vector...
|
|
WO/2022/138888A1 |
The purpose of the present invention is to provide a compound having a tetrahydroquinoline skeleton, said compound having ferroptosis inhibitory action and exhibiting a treatment effect or a prevention effect for a disease, disorder, or ...
|
